EXHIBIT 99.1


Contact:

Media:                         Investors:
Daniel Budwick                 Ann Tanabe                        Hershel Berry
BMC Communications             Encysive Pharmaceuticals          The Trout Group
(212) 477-9007 ext. 14         (713) 796-8822                    (415) 392-3385


FOR IMMEDIATE RELEASE

     ENCYSIVE PHARMACEUTICALS APPOINTS J. KEVIN BUCHI TO BOARD OF DIRECTORS


HOUSTON, TX, JUNE 23, 2004 - Encysive Pharmaceuticals (NASDAQ:ENCY) today
announced that J. Kevin Buchi, 49, has been elected to the Company's Board of
Directors and appointed to serve on the Audit Committee. Mr. Buchi's appointment
brings to 11 the number of directors.

Mr. Buchi is Senior Vice President, Finance and Chief Financial Officer of
Cephalon, Inc. Mr. Buchi has helped guide Cephalon through several financings,
product and company acquisitions, and in the development and execution of
successful growth strategies. Prior to Cephalon, Mr. Buchi held positions at
E.I. duPont de Nemours and Company, PricewaterhouseCoopers, and Eastman Kodak
Co. Mr. Buchi holds a BA in Chemistry from Cornell University and an MBA from
Kellogg Graduate School of Management at Northwestern University. He is also a
Certified Public Accountant.

"Kevin's extensive experience and success in the biotechnology industry will be
invaluable as we move closer towards the commercialization of Thelin(TM), our
lead product candidate in Phase III development for pulmonary arterial
hypertension," said John M. Pietruski, Chairman of the Board of Encysive
Pharmaceuticals. "We are pleased to welcome Kevin to the Board and will look to
his expertise in the coming months and years."

ABOUT ENCYSIVE PHARMACEUTICALS

Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, Thelin, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.

This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of


                                                                    EXHIBIT 99.1


research and clinical goals and milestones of product candidates, attainment of
required government approvals, sales levels of our products and availability of
financing, and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The company undertakes no duty to update or revise these
forward-looking statements.

                                      # # #